TSXV:CLAS.H - Post by User
Comment by
WORKINMONTANAon Feb 14, 2019 11:45am
133 Views
Post# 29364356
RE:RE:RE:Great
RE:RE:RE:GreatRiskyBiz928 wrote: Hey Penny, when was the partnership news promised? I must have missed that one. It would be great for big pharma to get in on this.
Another one other than the Shareholder letter April 2018
News release September 20, 2018
LINK >>> CEO Stating Partnerships said Robert Farrell, President and CEO of Kalytera. “We expect to initiate the Phase 3 clinical study in prevention of acute GVHD within the next 12 months. Our plans for this program are as follows: (1) we plan to announce interim data from the ongoing Phase 2 study later this year; (2) we will complete the Phase 2 study in Q2 2019; and (3) we plan to initiate the Phase 3 clinical study during Q3 2019. We have also begun the process of seeking corporate partnering opportunities for both of our GVHD programs. The objective of such a partnership will be to provide a non-dilutive source of funding for the programs, as well as future revenue through licensing fees, milestone payments and royalties.”